JP2025510813A - Ｔｙｋ２阻害剤及びその使用 - Google Patents

Ｔｙｋ２阻害剤及びその使用 Download PDF

Info

Publication number
JP2025510813A
JP2025510813A JP2024556626A JP2024556626A JP2025510813A JP 2025510813 A JP2025510813 A JP 2025510813A JP 2024556626 A JP2024556626 A JP 2024556626A JP 2024556626 A JP2024556626 A JP 2024556626A JP 2025510813 A JP2025510813 A JP 2025510813A
Authority
JP
Japan
Prior art keywords
compound
patient
weeks
psoriasis
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510813A5 (enExample
Inventor
ジョン コリス，アラン
ホサグラハラ，ヴィナヤック
スリヴァスタヴァ，バスカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2025510813A publication Critical patent/JP2025510813A/ja
Publication of JP2025510813A5 publication Critical patent/JP2025510813A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024556626A 2022-03-25 2023-03-24 Ｔｙｋ２阻害剤及びその使用 Pending JP2025510813A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263269943P 2022-03-25 2022-03-25
US63/269,943 2022-03-25
US202263371033P 2022-08-10 2022-08-10
US63/371,033 2022-08-10
US202363490664P 2023-03-16 2023-03-16
US63/490,664 2023-03-16
PCT/US2023/064902 WO2023183901A1 (en) 2022-03-25 2023-03-24 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025510813A true JP2025510813A (ja) 2025-04-15
JP2025510813A5 JP2025510813A5 (enExample) 2026-03-31

Family

ID=88102041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556626A Pending JP2025510813A (ja) 2022-03-25 2023-03-24 Ｔｙｋ２阻害剤及びその使用

Country Status (10)

Country Link
US (1) US20250213572A1 (enExample)
EP (1) EP4499104A4 (enExample)
JP (1) JP2025510813A (enExample)
KR (1) KR20240165963A (enExample)
AU (1) AU2023237900A1 (enExample)
CA (1) CA3246157A1 (enExample)
CL (1) CL2024002824A1 (enExample)
MX (1) MX2024011693A (enExample)
TW (1) TW202345799A (enExample)
WO (1) WO2023183901A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263861A2 (en) * 2023-06-23 2024-12-26 Dana-Farber Cancer Institute, Inc. Methods of treating chronic lymphocytic leukemia
EP4780462A1 (en) * 2023-09-21 2026-07-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN122341608A (zh) * 2023-11-24 2026-07-03 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2026032374A1 (zh) * 2024-08-07 2026-02-12 正大天晴药业集团股份有限公司 含联环的化合物用于治疗银屑病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
MX2024011693A (es) 2024-11-08
US20250213572A1 (en) 2025-07-03
CA3246157A1 (en) 2023-09-28
EP4499104A1 (en) 2025-02-05
AU2023237900A1 (en) 2024-10-10
EP4499104A4 (en) 2025-09-03
KR20240165963A (ko) 2024-11-25
TW202345799A (zh) 2023-12-01
CL2024002824A1 (es) 2025-02-14
WO2023183901A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7724241B2 (ja) Ｉｒａｋ分解剤の結晶形態
US20250213572A1 (en) Tyk2 inhibitors and uses thereof
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
TWI783978B (zh) Tyk2抑制劑、其用途及生產方法
CN113348021B (zh) Tyk2抑制剂和其用途
EP3145513B1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP2025534698A (ja) Ｉｒａｋ４デグレーダーの塩の形態
US20230322754A1 (en) Irak inhibitors and uses thereof
JP2026009991A (ja) ウイルス感染、炎症又は癌の処置におけるバイオマーカー及び使用
WO2024064080A1 (en) Stat6 degraders and uses thereof
JP2024506858A (ja) Ｇｐｒ８４アンタゴニストおよびその使用
US20240262830A1 (en) Ire1a modulators and uses thereof
AU2023317742A1 (en) Substituted pyridone gpr84 antagonists and uses thereof
JP2025510844A (ja) Ｔｙｋ２阻害剤の合成及びその中間体
JP2025510826A (ja) Ｔｙｋ２阻害剤の固体形態及び使用方法
US20250221997A1 (en) Tyk2 inhibitor formulations and methods of making the same
JP2025527250A (ja) ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025503491A (ja) Ｏｘｅｒ１アンタゴニスト及びその使用
CN118973583A (zh) Tyk2抑制剂及其用途
AU2024344754A1 (en) Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323